Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Condensates are important for cells to coordinate and control different biochemical processes by compartmentalizing them. Condensatopathies occur when proteins are incorrectly sequestered or excluded in condensates as is seen in neurodegeneration and cardiovascular disease.
Dewpoint aims to prevent harmful protein sequestration by restoring healthy condensate properties and functions. Using a combination of genetics, imaging, mapping and medicinal chemistry, Dewpoint is using their condensate platform to produce novel targets that can then be used to develop life-changing medicines.